Trial Profile

A Single-arm, Prospective Study of Cyclosporine in Combination With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Refractory to Carfilzomib With High Expression of the Peptidylprolyl Isomerase A (PPIA) Gene in Myeloma Cells

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Ciclosporin (Primary) ; Dexamethasone (Primary)
Indications Multiple myeloma
Focus Adverse reactions

24 Jul 2025 Status changed from recruiting to completed.
22 Aug 2024 Planned End Date changed from 1 May 2024 to 1 May 2026.
22 Aug 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com